Published in Arch Gen Psychiatry on December 01, 2011
A model of placebo response in antidepressant clinical trials. Am J Psychiatry (2013) 1.46
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Early PTSD symptom trajectories: persistence, recovery, and response to treatment: results from the Jerusalem Trauma Outreach and Prevention Study (J-TOPS). PLoS One (2013) 1.16
A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res (2013) 0.90
A review of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord (2013) 0.88
The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry (2015) 0.85
Reducing eating disorder risk factors: a controlled investigation of a blended task-shifting/train-the-trainer approach to dissemination and implementation. Behav Res Ther (2014) 0.82
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry (2015) 0.82
A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology (Berl) (2014) 0.80
Trajectories of change in anxiety severity and impairment during and after treatment with evidence-based treatment for multiple anxiety disorders in primary care. Depress Anxiety (2013) 0.79
A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess (2014) 0.78
The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry (2013) 0.77
Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. J Subst Abuse Treat (2014) 0.77
Sudden gains in prolonged exposure and sertraline for chronic PTSD. Depress Anxiety (2013) 0.77
Increases in frontostriatal connectivity are associated with response to dorsomedial repetitive transcranial magnetic stimulation in refractory binge/purge behaviors. Neuroimage Clin (2015) 0.77
Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicine. Gerontology (2015) 0.77
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. Lancet Psychiatry (2017) 0.75
Targeted use of growth mixture modeling: a learning perspective. Stat Med (2016) 0.75
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Transl Psychiatry (2015) 0.75
GROUP-BASED SYMPTOM TRAJECTORIES IN INDICATED PREVENTION OF ADOLESCENT DEPRESSION. Depress Anxiety (2015) 0.75
Early Symptom Trajectories as Predictors of Treatment Outcome for Citalopram Versus Placebo. Am J Geriatr Psychiatry (2017) 0.75
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med (2008) 19.86
Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol Clin Exp Res (2000) 13.14
Distributional assumptions of growth mixture models: implications for overextraction of latent trajectory classes. Psychol Methods (2003) 12.46
Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med (2008) 11.44
Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics (1999) 10.82
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
Placebo response in studies of major depression: variable, substantial, and growing. JAMA (2002) 7.56
Antidepressants and the risk of suicidal behaviors. JAMA (2004) 7.08
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry (2004) 6.05
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
National patterns in antidepressant medication treatment. Arch Gen Psychiatry (2009) 4.82
Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry (2006) 4.30
Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ (2009) 3.97
Methods for testing theory and evaluating impact in randomized field trials: intent-to-treat analyses for integrating the perspectives of person, place, and time. Drug Alcohol Depend (2008) 3.09
A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry (1981) 2.76
A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther (2010) 2.74
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol (2008) 2.23
Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology (1994) 2.10
Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med (2009) 1.87
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry (2002) 1.67
Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol (2004) 1.65
Growth modeling with nonignorable dropout: alternative analyses of the STAR*D antidepressant trial. Psychol Methods (2011) 1.49
Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry (2009) 1.42
Trajectories of change in depression severity during treatment with antidepressants. Psychol Med (2009) 1.40
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol (2004) 1.40
Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry (2009) 1.38
Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry (2007) 1.26
The impact of restrictive entry criterion during the placebo lead-in period. Biometrics (2000) 1.21
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug Alcohol Depend (2009) 1.16
New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry (2007) 1.12
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry (2006) 1.10
Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J Psychiatr Res (2009) 1.09
Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry (2007) 1.07
Model Misspecification: Finite Mixture or Homogeneous? Stat Modelling (2008) 1.05
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol (2005) 1.05
Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv (2009) 1.04
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology (2007) 1.04
The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol (2001) 1.02
Latent Regression Analysis. Stat Modelling (2010) 1.02
Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology (1996) 0.94
Outcome definitions and predictors in depression. Psychother Psychosom (1998) 0.90
Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract (2007) 0.89
Modelling placebo response in depression trials using a longitudinal model with informative dropout. Eur J Pharm Sci (2008) 0.89
Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol (2007) 0.89
Is there a placebo problem in antidepressant trials? Curr Top Med Chem (2005) 0.87
Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull (2007) 0.85
Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry (1993) 0.82
Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry (1999) 0.81
Placebo response and antidepressant response. Am J Geriatr Psychiatry (2007) 0.79
Depression, antidepressants, and peripheral blood components. Neuro Endocrinol Lett (2008) 0.79
The introductory placebo washout: a retrospective evaluation. Psychiatry Res (1989) 0.77
Comparing onset of antidepressant action using a repeated measures approach and a traditional assessment schedule. Stat Med (2006) 0.76
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry (2004) 6.05
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci U S A (2004) 4.42
Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry (2006) 3.97
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 3.64
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry (2008) 3.51
Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med (2011) 3.36
Analyzing incomplete longitudinal clinical trial data. Biostatistics (2004) 2.82
A prospective cohort study investigating factors associated with depression during medical internship. Arch Gen Psychiatry (2010) 2.41
The role of default network deactivation in cognition and disease. Trends Cogn Sci (2012) 2.39
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry (2005) 2.36
Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res (2005) 2.35
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry (2008) 2.17
Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry (2010) 2.16
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry (2012) 2.10
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry (2002) 2.01
Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry (2002) 1.99
Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry (2004) 1.96
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res (2007) 1.86
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry (2003) 1.81
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res (2011) 1.80
Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry (2011) 1.76
Impairment of working memory maintenance and response in schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry (2008) 1.76
Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol Psychiatry (2005) 1.72
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
Impaired visual cortical plasticity in schizophrenia. Biol Psychiatry (2012) 1.67
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry (2002) 1.67
Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology (Berl) (2005) 1.67
Rare ADH variant constellations are specific for alcohol dependence. Alcohol Alcohol (2012) 1.66
Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol (2004) 1.65
Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry (2003) 1.64
Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry (2004) 1.64
Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history. Biol Psychiatry (2012) 1.62
Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly (2007) 1.62
Genetic and environmental predictors of early alcohol use. Biol Psychiatry (2006) 1.60
Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull (2002) 1.56
Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol (2005) 1.55
Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry (2005) 1.55
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry (2005) 1.52
Glutamate metabolism in major depressive disorder. Am J Psychiatry (2014) 1.52
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry (2006) 1.51
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull (2012) 1.50
Genome-wide association study of alcohol dependence implicates KIAA0040 on chromosome 1q. Neuropsychopharmacology (2011) 1.50
Striking differences in glucose and lactate levels between brain extracellular fluid and plasma in conscious human subjects: effects of hyperglycemia and hypoglycemia. J Cereb Blood Flow Metab (2002) 1.48
Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. Biol Psychiatry (2006) 1.47
Preliminary evidence for persistent abnormalities in amygdala volumes in adolescents and young adults with bipolar disorder. Bipolar Disord (2005) 1.47
A latent-class mixture model for incomplete longitudinal Gaussian data. Biometrics (2007) 1.45
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43
Corpus callosum in maltreated children with posttraumatic stress disorder: a diffusion tensor imaging study. Psychiatry Res (2008) 1.42
Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry (2007) 1.42
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med (2014) 1.39
Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci (2003) 1.35
Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry (2002) 1.34
Probing the pathophysiology of auditory/verbal hallucinations by combining functional magnetic resonance imaging and transcranial magnetic stimulation. Cereb Cortex (2007) 1.34
Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology (2010) 1.34
Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol Psychiatry (2005) 1.33
Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [¹¹C]raclopride. Biol Psychiatry (2010) 1.33
MAOA genotype, maltreatment, and aggressive behavior: the changing impact of genotype at varying levels of trauma. Biol Psychiatry (2008) 1.32
NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A (2012) 1.32
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) (2005) 1.31
Neural synchrony in schizophrenia: from networks to new treatments. Schizophr Bull (2007) 1.28
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry (2011) 1.26
The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets (2007) 1.25
Riluzole in the treatment of mood and anxiety disorders. CNS Drugs (2008) 1.24
Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis (2003) 1.23
Significance of adolescent neurodevelopment for the neural circuitry of bipolar disorder. Ann N Y Acad Sci (2004) 1.23
Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) (2007) 1.22
Why do delusions persist? Front Hum Neurosci (2009) 1.20
Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry (2011) 1.20
Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry (2004) 1.20
A novel, functional and replicable risk gene region for alcohol dependence identified by genome-wide association study. PLoS One (2011) 1.19
Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry (2007) 1.17
Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry (2002) 1.16
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug Alcohol Depend (2009) 1.16
Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry (2013) 1.14
Fore-period effect and stop-signal reaction time. Exp Brain Res (2005) 1.13
New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry (2007) 1.12
Decreased hippocampal volume on MRI is associated with increased extracellular glutamate in epilepsy patients. Epilepsia (2008) 1.11
Impact of intravenous nicotine on BOLD signal response to photic stimulation. Magn Reson Imaging (2002) 1.11
Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl) (2013) 1.10
GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets (2005) 1.10
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking. Biol Psychiatry (2005) 1.10
Linking microcircuit dysfunction to cognitive impairment: effects of disinhibition associated with schizophrenia in a cortical working memory model. Cereb Cortex (2012) 1.09
Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Berl) (2006) 1.06
Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry (2012) 1.06
Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcohol Clin Exp Res (2007) 1.05
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci (2015) 1.04
Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla. Biol Psychiatry (2011) 1.04
Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res (2007) 1.03
Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl) (2008) 1.03
The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology (2013) 1.02
Neural correlates of impulsivity in healthy males and females with family histories of alcoholism. Neuropsychopharmacology (2013) 1.02
Dimensional structure of DSM-5 posttraumatic stress disorder symptoms: results from the National Health and Resilience in Veterans Study. J Clin Psychiatry (2015) 1.02
Serotonin 1B receptor imaging in alcohol dependence. Biol Psychiatry (2010) 1.02
A broken filter: prefrontal functional connectivity abnormalities in schizophrenia during working memory interference. Schizophr Res (2012) 1.01